Natera Inc

• Natera shares pulled back due to broad profit-taking after recent peak levels. • Elevated valuations and insider share sales fueled recent short-term selling pressure. • Core fundamentals remain strong with robust volume growth across precision medicine portfolios.

• Natera's clinical milestones and Signatera validation bolstered investor confidence. • Management highlighted accelerating test adoption and long-term gross margin expansion. • Wall Street sentiment remains favorable with multiple analysts issuing buy ratings.

• Natera reported strong adoption for Signatera and positive Medicare reimbursement updates. • The company achieved robust top-line revenue growth with $2.31B annual revenue. • Analysts issued Buy ratings with an average price target of $342.35.

• ResMed gross margins contracted due to product mix shifts and elevated logistical expenses. • Concerns over GLP-1 weight-loss drugs create long-term uncertainty for CPAP market growth. • Increased competition and higher operating expenses are pressuring short-term profitability and investor sentiment.